1-4 of 4
Rolf W. Sparidans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models

Fan Lin, Mark C. de Gooijer, Diana Hanekamp, Gayathri Chandrasekaran, Levi C.M. Buil, Nishita Thota, Rolf W. Sparidans, Jos H. Beijnen, Tom Würdinger, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (5): 1286–1298.
https://doi.org/10.1158/1078-0432.CCR-16-1276
Published: 28 February 2017
View article titled, PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
Open the PDF for PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models in another window
Includes: Supplementary data
Journal Articles

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

M. Emmy M. Dolman, Evon Poon, Marli E. Ebus, Ilona J.M. den Hartog, Carel J.M. van Noesel, Yann Jamin, Albert Hallsworth, Simon P. Robinson, Kevin Petrie, Rolf W. Sparidans, Robbert J. Kok, Rogier Versteeg, Huib N. Caron, Louis Chesler, Jan J. Molenaar
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5100–5109.
https://doi.org/10.1158/1078-0432.CCR-15-0313
Published: 12 November 2015
View article titled, Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Open the PDF for Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice

Seng Chuan Tang, Rolf W. Sparidans, Ka Lei Cheung, Tatsuki Fukami, Selvi Durmus, Els Wagenaar, Tsuyoshi Yokoi, Bart J.M. van Vlijmen, Jos H. Beijnen, Alfred H. Schinkel
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3133–3145.
https://doi.org/10.1158/1078-0432.CCR-13-1759
Published: 12 June 2014
View article titled, P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice
Open the PDF for P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice in another window
Includes: Supplementary data
Journal Articles

Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer

Mirjam Crul, Nadja E. Schoemaker, Dick Pluim, Marc Maliepaard, René W. M. Underberg, Margaret Schot, Rolf W. Sparidans, Paul Baas, Jos H. Beijnen, Nico van Zandwijk, Jan H. M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3526–3533.
Published: 23 September 2003
View article titled, Randomized Phase I Clinical and Pharmacologic Study of Weekly <em>versus</em> Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for Randomized Phase I Clinical and Pharmacologic Study of Weekly <em>versus</em> Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer in another window